Defining genomic, transcriptomic, proteomic, epigenetic, and phenotypic biomarkers with prognostic capability in male breast cancer: a systematic review.

[1]  V. Speirs,et al.  Analysis of the Clinical Advancements for BRCA-Related Malignancies Highlights the Lack of Treatment Evidence for BRCA-Positive Male Breast Cancer , 2022, Cancers.

[2]  N. Sang,et al.  Stanniocalcin 2 (STC2): a universal tumour biomarker and a potential therapeutical target , 2022, Journal of experimental & clinical cancer research : CR.

[3]  D. Hanahan.  Hallmarks of Cancer: New Dimensions. , 2022, Cancer discovery.

[4]  R. Greil,et al.  Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03) , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Bowen Li,et al.  DACH1 inhibits breast cancer cell invasion and metastasis by down-regulating the transcription of matrix metalloproteinase 9 , 2021, Cell Death Discovery.

[6]  Shu-Hsing Wu,et al.  DDX3 modulates the tumor microenvironment via its role in endoplasmic reticulum-associated translation , 2021, iScience.

[7]  R. Leon-Ferre,et al.  A practical guide to endocrine therapy in the management of estrogen receptor-positive male breast cancer , 2021, Breast Cancer Management.

[8]  S. Fox,et al.  Transcriptome of Male Breast Cancer Matched with Germline Profiling Reveals Novel Molecular Subtypes with Possible Clinical Relevance , 2021, Cancers.

[9]  J. Lubiński,et al.  Genetic predisposition to male breast cancer in Poland , 2021, BMC Cancer.

[10]  S. Fox,et al.  Male breast cancer: an update , 2021, Virchows Archiv.

[11]  V. Villegas,et al.  Intrinsic Subtypes and Androgen Receptor Gene Expression in Primary Breast Cancer. A Meta-Analysis , 2021, Biology.

[12]  F. Couch,et al.  Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores , 2021, Journal of the National Cancer Institute.

[13]  K. S. Fan,et al.  Top 100 cited articles in male breast cancer: A bibliometric analysis. , 2021, Breast disease.

[14]  Yiyuan Liu,et al.  The Global, Regional, and National Burden and Trends of Breast Cancer From 1990 to 2019: Results From the Global Burden of Disease Study 2019 , 2021, Frontiers in Oncology.

[15]  Quirine F. Manson,et al.  Cytoplasmic DDX3 as prognosticator in male breast cancer , 2021, Virchows Archiv.

[16]  E. Mayo-Wilson,et al.  The PRISMA 2020 statement: an updated guideline for reporting systematic reviews , 2021, Systematic Reviews.

[17]  E. Winer,et al.  Tumor subtypes and survival in male breast cancer , 2021, Breast Cancer Research and Treatment.

[18]  F. Marmé,et al.  Efficacy of Endocrine Therapy for the Treatment of Breast Cancer in Men: Results from the MALE Phase 2 Randomized Clinical Trial. , 2021, JAMA oncology.

[19]  I. Ellis,et al.  The androgen receptor is a tumor suppressor in estrogen receptor–positive breast cancer , 2021, Nature Medicine.

[20]  H. Rugo,et al.  Alpelisib Plus Fulvestrant for PIK3CA-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Advanced Breast Cancer: Final Overall Survival Results From SOLAR-1. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  E. Winer,et al.  A Randomized Placebo Controlled Phase II Trial Evaluating Exemestane with or without Enzalutamide in Patients with Hormone Receptor–Positive Breast Cancer , 2020, Clinical Cancer Research.

[22]  P. V. van Diest,et al.  Elastosis in ERα-positive male breast cancer , 2020, Virchows Archiv.

[23]  P. V. van Diest,et al.  Methylation Profile of X-Chromosome–Related Genes in Male Breast Cancer , 2020, Frontiers in Oncology.

[24]  M. Miccoli,et al.  Androgen receptor expression inversely correlates with histological grade and N stage in ER+/PgRlow male breast cancer , 2020, Breast Cancer Research and Treatment.

[25]  E. D. de Vries,et al.  High hepatocyte growth factor expression in primary tumor predicts better overall survival in male breast cancer , 2020, Breast Cancer Research.

[26]  M. Gutman,et al.  Breast Cancer in Men: A Single Center Experience Over a Period of 22 years. , 2020, The Israel Medical Association journal : IMAJ.

[27]  A. Jemal,et al.  Subtype-Specific Breast Cancer Incidence Rates in Black versus White Men in the United States , 2019, JNCI cancer spectrum.

[28]  R. Alvarez,et al.  Male patient with metastatic stage IV breast cancer achieves complete remission on second line Abemaciclib, Fulvestrant and Leuprolide: A case report , 2019, Molecular and clinical oncology.

[29]  C. Tufanaru,et al.  Chapter 7: Systematic Reviews of Etiology and Risk , 2020, JBI Manual for Evidence Synthesis.

[30]  P. De,et al.  ER+ metastatic breast cancer: past, present, and a prescription for an apoptosis-targeted future. , 2019, American journal of cancer research.

[31]  P. V. van Diest,et al.  Expression of hypoxia-induced proteins in ductal carcinoma in situ and invasive cancer of the male breast , 2019, Journal of Clinical Pathology.

[32]  L. Fashoyin-Aje,et al.  FDA Approval Summary: Palbociclib for Male Patients with Metastatic Breast Cancer , 2019, Clinical Cancer Research.

[33]  P. Bult,et al.  The molecular genetic make-up of male breast cancer. , 2019, Endocrine-related cancer.

[34]  Q. Song,et al.  Effects of HER2 status on the prognosis of male breast cancer: a population-based study , 2019, OncoTargets and therapy.

[35]  S. André,et al.  Male breast cancer: Specific biological characteristics and survival in a Portuguese cohort. , 2019, Molecular and clinical oncology.

[36]  P. V. van Diest,et al.  Promoter hypermethylation in ductal carcinoma in situ of the male breast. , 2019, Endocrine-related cancer.

[37]  R. Salunga,et al.  Trans-aTTom: Breast Cancer Index for prediction of endocrine benefit and late distant recurrence (DR) in patients with HR+ breast cancer treated in the adjuvant tamoxifen—To offer more? (aTTom) trial. , 2019, Journal of Clinical Oncology.

[38]  S. Pasricha,et al.  Immunophenotyping of male breast cancer - Experience at a tertiary care centre , 2019, Indian journal of pathology & microbiology.

[39]  A. Shaaban.  Pathology of the male breast , 2019, Diagnostic Histopathology.

[40]  B. Bonanni,et al.  Insight into genetic susceptibility to male breast cancer by multigene panel testing: Results from a multicenter study in Italy , 2019, International journal of cancer.

[41]  F. Couch,et al.  Male breast cancer in the United States: Treatment patterns and prognostic factors in the 21st century , 2019, Cancer.

[42]  B. Bonanni,et al.  Contribution of MUTYH Variants to Male Breast Cancer Risk: Results From a Multicenter Study in Italy , 2018, Front. Oncol..

[43]  Kongming Wu,et al.  Dachshund 1 is Differentially Expressed Between Male and Female Breast Cancer: A Matched Case‐Control Study of Clinical Characteristics and Prognosis , 2018, Clinical breast cancer.

[44]  Sara R. Selitsky,et al.  Male breast cancer: a disease distinct from female breast cancer , 2018, Breast Cancer Research and Treatment.

[45]  E. Provenzano,et al.  Stanniocalcin 2 expression is associated with a favourable outcome in male breast cancer , 2018, The journal of pathology. Clinical research.

[46]  S. Bianchi,et al.  Gene-specific methylation profiles in BRCA-mutation positive and BRCA-mutation negative male breast cancers , 2018, Oncotarget.

[47]  Quirine F. Manson,et al.  Characterizing steroid hormone receptor chromatin binding landscapes in male and female breast cancer , 2018, Nature Communications.

[48]  Melissa P. Murray,et al.  Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[49]  S. Fox,et al.  BRCA2 carriers with male breast cancer show elevated tumour methylation , 2017, BMC Cancer.

[50]  H. Nevanlinna,et al.  CHEK2 c.1100delC mutation is associated with an increased risk for male breast cancer in Finnish patient population , 2017, BMC Cancer.

[51]  P. V. van Diest,et al.  Pathological characterisation of male breast cancer: Results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program. , 2017, European journal of cancer.

[52]  I. Ellis,et al.  Characterisation of male breast cancer: a descriptive biomarker study from a large patient series , 2017, Scientific Reports.

[53]  A. Bardia,et al.  Phase (Ph) 1 study of oral seviteronel (VT-464), a dual CYP17-Lyase (L) inhibitor and androgen receptor (AR) antagonist, in patients (pts) with advanced AR+ triple negative (TNBC) or estrogen receptor (ER)+ breast cancer (BC). , 2016 .

[54]  I. Fentiman.  Male breast cancer is not congruent with the female disease. , 2016, Critical reviews in oncology/hematology.

[55]  J. Jakubowicz,et al.  Androgen receptor in male breast cancer. , 2015, Polish journal of pathology : official journal of the Polish Society of Pathologists.

[56]  P. Diest,et al.  Tracing differences between male and female breast cancer: both diseases own a different biology , 2015, Histopathology.

[57]  R. Masetti,et al.  X chromosome gain in male breast cancer. , 2015, Human pathology.

[58]  C. Hudis,et al.  Results from a phase 2 study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer (TNBC). , 2015 .

[59]  M. Ringnér,et al.  Genome methylation patterns in male breast cancer – Identification of an epitype with hypermethylation of polycomb target genes , 2015, Molecular oncology.

[60]  F. H. Shandiz,et al.  Hormone receptor expression and clinicopathologic features in male and female breast cancer. , 2015, Asian Pacific journal of cancer prevention : APJCP.

[61]  A. Adamczyk,et al.  Lymphatic and blood vessels in male breast cancer. , 2015, Anticancer research.

[62]  Kathryn J Ruddy,et al.  The Epidemiology of Male Breast Cancer , 2015, Current Oncology Reports.

[63]  P. Radice,et al.  Association of SULT1A1 Arg213His polymorphism with male breast cancer risk: results from a multicenter study in Italy , 2014, Breast Cancer Research and Treatment.

[64]  Zhipeng Wang,et al.  Androgen receptor expression in male breast cancer predicts inferior outcome and poor response to tamoxifen treatment. , 2014, European journal of endocrinology.

[65]  S. Fox,et al.  Nuclear HIF1A expression is strongly prognostic in sporadic but not familial male breast cancer , 2014, Modern Pathology.

[66]  A. Adamczyk,et al.  The biological markers and results of treatment in male breast cancer patients. The Cracow experience. , 2014, Neoplasma.

[67]  S. Tommasi,et al.  Male breast cancer: genetics, epigenetics, and ethical aspects. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[68]  P. Diest,et al.  Analysis of copy number changes on chromosome 16q in male breast cancer by multiplex ligation-dependent probe amplification , 2013, Modern Pathology.

[69]  S. Tommasi,et al.  Different methylation and MicroRNA expression pattern in male and female familial breast cancer , 2013, Journal of cellular physiology.

[70]  P. V. van Diest,et al.  Prognostic Value of Mitotic Index and Bcl2 Expression in Male Breast Cancer , 2013, PloS one.

[71]  P. Radice,et al.  Association of low-penetrance alleles with male breast cancer risk and clinicopathological characteristics: results from a multicenter study in Italy , 2013, Breast Cancer Research and Treatment.

[72]  P. V. van Diest,et al.  Differential Expression of Growth Factor Receptors and Membrane-Bound Tumor Markers for Imaging in Male and Female Breast Cancer , 2013, PloS one.

[73]  M. Așchie,et al.  Clinico-pathological and molecular subtypes of male breast carcinoma according to immunohistochemistry. , 2013, Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie.

[74]  I. Hedenfalk,et al.  High proliferation is associated with inferior outcome in male breast cancer patients , 2013, Modern Pathology.

[75]  Hong-fei Ji,et al.  Long CAG Repeat Sequence and Protein Expression of Androgen Receptor Considered as Prognostic Indicators in Male Breast Carcinoma , 2012, PloS one.

[76]  P. V. van Diest,et al.  Immunophenotyping of male breast cancer , 2012, Histopathology.

[77]  Mitko Veta,et al.  Prognostic value of automatically extracted nuclear morphometric features in whole slide images of male breast cancer , 2012, Modern Pathology.

[78]  P. V. van Diest,et al.  Promoter hypermethylation in male breast cancer: analysis by multiplex ligation-dependent probe amplification , 2012, Breast Cancer Research.

[79]  P. Diest,et al.  Fibrotic focus and hypoxia in male breast cancer , 2012, Modern Pathology.

[80]  P. V. van Diest,et al.  Oncogene amplification in male breast cancer: analysis by multiplex ligation-dependent probe amplification , 2012, Breast Cancer Research and Treatment.

[81]  P. Diest,et al.  Molecular subtyping of male breast cancer by immunohistochemistry , 2012, Modern Pathology.

[82]  G. Ball,et al.  A comparative biomarker study of 514 matched cases of male and female breast cancer reveals gender-specific biological differences , 2012, Breast Cancer Research and Treatment.

[83]  M. Ringnér,et al.  Gene expression profiling of primary male breast cancers reveals two unique subgroups and identifies N-acetyltransferase-1 (NAT1) as a novel prognostic biomarker , 2012, Breast Cancer Research.

[84]  A. Ashworth,et al.  Genetic Variants at Chromosomes 2q35, 5p12, 6q25.1, 10q26.13, and 16q12.1 Influence the Risk of Breast Cancer in Men , 2011, PLoS genetics.

[85]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[86]  M. Ringnér,et al.  High-resolution genomic profiling of male breast cancer reveals differences hidden behind the similarities with female breast cancer , 2011, Breast Cancer Research and Treatment.

[87]  M. Gariboldi,et al.  Gene expression analysis reveals a different transcriptomic landscape in female and male breast cancer , 2011, Breast Cancer Research and Treatment.

[88]  J. Bergh,et al.  Multidisciplinary meeting on male breast cancer: summary and research recommendations. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[89]  R. Kanthan,et al.  Expression of cell cycle proteins in male breast carcinoma , 2010, World journal of surgical oncology.

[90]  I. Fentiman.  Male breast cancer: a review , 2009, Ecancermedicalscience.

[91]  A. Mansoor,et al.  COMPARATIVE ANALYSIS OF ESTROGEN, PROGESTERONE, C-ERBB-2 RECEPTOR STATUS OF AGE MATCHED MALE AND FEMALE BREAST CARCINOMA , 2009 .

[92]  J. Soares,et al.  Male and Female Breast Cancer – Differences in DNA Ploidy, p21 and p53 Expression Reinforce the Possibility of Distinct Pathways of Oncogenesis , 2007, Pathobiology.

[93]  J. Soares,et al.  Evaluation of ERBB2 Gene Status and Chromosome 17 Anomalies in Male Breast Cancer , 2006, The American journal of surgical pathology.

[94]  W. Gerald,et al.  An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen , 2006, Oncogene.

[95]  J. Foekens,et al.  Clinical relevance of biologic factors in male breast cancer , 2001, Breast Cancer Research and Treatment.

[96]  M. Teresiak,et al.  BRCA2 mutations and androgen receptor expression as independent predictors of outcome of male breast cancer patients. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[97]  M. Huszar,et al.  Oncogenes in Male Breast Cancer , 2003, American journal of clinical oncology.

[98]  A. Goldhirsch,et al.  Recognizing features that are dissimilar in male and female breast cancer: expression of p21Waf1 and p27Kip1 using an immunohistochemical assay. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[99]  L. Green,et al.  Role of Expression of Cell Cycle Inhibitor p27 and MIB‐1 in Predicting Lymph Node Metastasis in Male Breast Carcinoma , 2002, The breast journal.

[100]  R. Brentani,et al.  Expression of c-erbB-2, p53 and c-myc proteins in male breast carcinoma: Comparison with traditional prognostic factors and survival. , 2001, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[101]  G. Groisman,et al.  Angiogenesis, p53, and c‐erbB‐2 immunoreactivity and clinicopathological features in male breast cancer , 2000, Journal of surgical oncology.

[102]  L. Chiusa,et al.  Nuclear morphometry in male breast carcinoma: Association with cell proliferative activity, oncogene expression, DNA content and prognosis , 2000, International journal of cancer.

[103]  L. Chiusa,et al.  Oncogenes and male breast carcinoma: c-erbB-2 and p53 coexpression predicts a poor survival. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[104]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[105]  L. Chiusa,et al.  Androgen receptor expression in male breast carcinoma: lack of clinicopathological association , 1999, British Journal of Cancer.

[106]  L. Kass,et al.  Proliferative activity and steroid hormone receptor status in male breast carcinoma , 1998, Journal of Steroid Biochemistry and Molecular Biology.

[107]  J. Donohue,et al.  Molecular markers in male breast carcinoma , 1998, Cancer.

[108]  J. Hurlimann,et al.  Comparison of prognostic markers detected by immunohistochemistry in male and female breast carcinomas. , 1996, European journal of cancer.

[109]  S. Heys,et al.  Male breast cancer: clinico-pathological features, immunocytochemical characteristics and prognosis. , 1996, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[110]  L. Chiusa,et al.  Proliferative activity is a significant prognostic factor in male breast carcinoma. , 1994, The American journal of pathology.